Esterberg E, Iyer S, Nagar SP, Davis KL, Tannir NM. Real-world treatment patterns and clinical outcomes among patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2024 Apr;22(2):115-125.e. doi: 10.1016/j.clgc.2023.09.009
Bellmunt J, Chang J, Pavilack-Kirker M, Cappelleri JC, Costa N, Esterberg E, Kearney M, Hitchens A, Candrilli SD, Ajmera M. Evaluating real-world characteristics of patients with advanced urothelial carcinoma eligible for avelumab maintenance therapy: a multi-country retrospective medical chart review. Clin Genitourin Cancer. 2023 Aug;21(4):459-66. doi: 10.1016/j.clgc.2023.03.011
Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R, Martinez D, Garcia de Albeniz Martinez X. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002
Morgans A, Grewal S, Hepp Z, Fuldeore R, Odak S, Macahilig C, Shillington A, Sonpavde G. Clinical and patient-reported outcomes of advanced urothelial carcinoma following discontinuation of pd-1/l1 inhibitor therapy. Clin Genitourin Cancer. 2022 Aug 5. doi: 10.1016/j.clgc.2022.08.002
Fan W, Nittala MG, Wykoff CC, Brown DM, Uji A, Hemert JV, Fleming A, Robertson G, Sadda SR, Ip M. New biomarker quantifying the effect of anti-vegf therapy in eyes with proliferative diabetic retinopathy on ultra-wide field fluorescein angiography: recovery study. Retina - J Ret Vit Dis. 2022 Mar 1;42(3):426-33. doi: 10.1097/IAE.0000000000003358
Magrey M, Yi E, Wolin D, Price M, Chirila C, Davenport E, Park Y. Understanding barriers in the pathway to diagnosis of ankylosing spondylitis: results from a US survey of 1690 physicians from 10 specialties. ACR Open Rheumatol. 2020 Oct;2(10):616-26. doi: 10.1002/acr2.11179
Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273